March 9, 2009, Bernstein Liebhard LLP is investigating the proposed merger of Schering-Plough Corporation (“Schering-Plough” or the “Company”) (NYSE: SGP) and Merck & Co., Inc. (“Merck”) (NYSE: MRK) (the “Merger”).
The Merck & Schering Plough Merger
Under the terms of the Merger, Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Further, each Merck share will automatically become a share of the combined company. Upon closing of the transaction, Merck shareholders are expected to own approximately 68 percent of the combined company, and Schering-Plough shareholders are expected to own approximately 32 percent.
Schering-Plough is incorporated in New Jersey and maintains its corporate headquarters at 2000 Galloping Hill Road, Kenilworth, NJ 07033. Schering-Plough discovers, develops, manufactures, and sells pharmaceuticals worldwide. It operates in three segments: Prescription Pharmaceuticals, Animal Health, and Consumer Health Care.
Merck is incorporated in New Jersey and maintains its corporate headquarters at One Merck Drive, Whitehouse Station, NJ 08889-0100. Merck is a global research pharmaceutical company that discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health. Merck’s operations are principally managed on a products basis and are comprised of two reportable segments: the Pharmaceutical segment and the Vaccines and Infectious Diseases segment.
Contact Lawyers Investigating the Schering-Plough & Merck Merger Today
If you are a current holder of Schering-Plough and/or Merck shares and wish to discuss the above matter with us, or have any questions concerning your rights and interests as a shareholder of Schering-Plough and/or Merck with regard to the Merger, please contact the following: U. Seth Ottensoser of Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016 at (877) 779-1414 (toll free) or (212) 779-1414 or by email at email@example.com.